CG Oncology Files 8-K

TL;DR

CG Oncology dropped an 8-K, check it for updates.

AI Summary

CG Oncology, Inc. filed an 8-K on May 24, 2024, to report on several items including Regulation FD disclosures, other events, and financial statements. The filing does not contain specific dollar amounts or detailed event descriptions within the provided text, but it serves as a formal notification to the SEC.

Why It Matters

This filing indicates CG Oncology is making material disclosures to the SEC, which could impact investor understanding of the company's current status and future outlook.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain information that inherently increases risk.

Key Numbers

• 001-41925 — SEC File Number (Identifies the company's filing with the SEC.)
• 37-1611499 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• CG Oncology, Inc. (company) — Registrant
• May 24, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Irvine, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CGON The Nasdaq Global Se

Filing Documents

• ck0001991792-20240524.htm (8-K) — 57KB
• ck0001991792-ex99_1.htm (EX-99.1) — 30KB
• img89521117_0.jpg (GRAPHIC) — 12KB
• 0000950170-24-064309.txt ( ) — 231KB
• ck0001991792-20240524.xsd (EX-101.SCH) — 26KB
• ck0001991792-20240524_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On May 24, 2024, CG Oncology, Inc. (the " Company ") issued a press release entitled "CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting." The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. On May 24, 2024, the Company posted an updated corporate presentation on the Company's website. Investors may access the presentation by visiting the "Investor Relations" section of the Company's website at www.cgoncology.com . The Company plans to use its website to disseminate future updates to its corporate presentation and does not intend to file or furnish a Form 8-K alerting investors each time the presentation is updated. The information furnished under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing. By furnishing the information in this Item 7.01, the Company makes no admission as to the materiality of Item 7.01 in this report or the presentation available on the Company's website. The information contained in the corporate presentation is summary information that is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Item 7.01, although it may do so from time to time as its management believes is appropriate or as required by applicab

Forward Looking Statements

Forward Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the potential therapeutic benefits of cretostimogene in combination with pembrolizumab for high-risk NMIBC patients and the importance of the data as they relate to addressing bladder cancer. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in our business, including, without limitation: reported topline data is based on preliminary analysis of key efficacy and safety data is subject to more audit and verification procedures that could result in material changes in the final data; additional patient data related to cretostimogene in combination with pembrolizumab that continues to become available may be inconsistent with the data produced as of the date hereof, and further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our annual report on Form 10-K and any subsequent filings with the SEC (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their ent

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated May 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CG Oncology, Inc. Date: May 24, 2024 By: /s/ Josh Patterson Name: Josh Patterson Title: General Counsel and Chief Compliance Officer

View Full Filing

View this 8-K filing on SEC EDGAR